PRIMARY STUDY
Efficacy and Safety of Medical Marijuana in Migraine Headache: A Systematic Review
Key Findings: This systematic review found that medical cannabis significantly reduced the length and frequency of migraines, with no severe adverse effects.
Type of Study: Clinical Meta-analysis
Study Sample Size: 9
Study Result: Positive
Research Location(s): United States
Year of Pub: 2022
Cannabinoids Studied: Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype I, Chemotype II
Terpenes Studied: ß-Caryophyllene, Myrcene
DOSING DETAILS 
Study Dosing Objective: Effective Dose,
Established Protocol: Effective dose
Route of Administration: Inhalation, Oral (Ingestion), Sublingual/Oromucosal
Cannabinoid Ratio: (THC : CBD) 19 : 9 
Dosage Form: 19% THC or 19% THC with 9% CBD
Dosing Regimen: 200 mg was effective in reducing migraine pain by 55% 200 mg of THC with CBD was superior to amitriptyline
Adverse Events: Somnolence with an edible form of medical cannabis. 23.1% in one study reported adverse effects, and 1.3% of those cases discontinued medical cannabis, but no severe adverse effects were reported.
Citation: Sherpa ML, et al. Efficacy and Safety of Medical Marijuana in Migraine Headache: A Systematic Review. Cureus. 2022; 14:e32622. doi: 10.7759/cureus.32622
Authors: Sherpa ML, Shrestha N, Ojinna BT, Ravi N, Shantha Kumar V, Choday S, Parisapogu A, Tran HH, Kc A, Elshaikh AO
